Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Research Article

Pharmacokinetics of Benzoic Acid, 4-[[(2-Hydroxyethyl)Amino]Carbonyl]- Methyl Ester from Portulaca Oleracea L. in Rats after Intravenous and Oral Administrations Using UHPLC-ESI-Q-TOF/MS

Author(s): Haoran Xu, Zheming Ying, Lina Wang, Wenjie Zhang, Xixiang Ying* and Guanlin Yang*

Volume 16, Issue 5, 2020

Page: [601 - 607] Pages: 7

DOI: 10.2174/1573412915666190320154857

Price: $65

Abstract

Objective: The aim of this study is to investigate the pharmacokinetics of benzoic acid, 4- [[(2-hydroxyethyl)amino]carbonyl], methyl ester in rats after intravenous and oral administrations at doses of 3 mL/kg.

Methods: A rapid, high selective ultra-high performance liquid chromatographic electrospray quadrupole- time of flight mass spectrometry (UHPLC-ESI-Q-TOF/MS) method was applied to investigate the pharmacokinetics of benzoic acid, 4-[[(2-hydroxyethyl)amino]carbonyl]-, methyl ester with p-coumaric acid as internal standard (IS) in rats after intravenously and orally dosed.

Results: The pharmacokinetic data of benzoic acid, 4-[[(2-hydroxyethyl)amino]carbonyl]-, methyl ester was analyzed in the two-compartment open model. The main pharmacokinetic parameters were, respectively, 36.474 μg·h/mL, 12.59 μg·h/mL (AUC0→∞), and T1/2α was 0.14 h, 0.359 h; T1/2β was 3.046 h, 5.646 h after intravenous and oral administrations.

Conclusion: Benzoic acid, 4-[[(2-hydroxyethyl)amino] carbonyl]-, methyl ester was rapidly distributed in rat’s plasma with the absolute bioavailability of 34.5%.

Keywords: Portulaca oleracea L., Benzoic acid, 4-[[(2-hydroxyethyl)amino]carbonyl], methyl ester, pharmacokinetics, ultrahigh performance liquid chromatography-electrospray quadrupole-time of flight mass spectrometry, rat.

« Previous Next »
Graphical Abstract

[1]
Rashed, A.N.; Afifi, F.U.; Disi, A.M. Simple evaluation of the wound healing activity of a crude extract of Portulaca oleracea L. (growing in Jordan) in Mus musculus JVI-1. J. Ethnopharmacol., 2003, 88(2-3), 131-136.
[http://dx.doi.org/10.1016/S0378-8741(03)00194-6] [PMID: 12963132]
[2]
Tian, J.L.; Liang, X.; Gao, P.Y.; Li, D.Q.; Sun, Q.; Li, L.Z.; Song, S.J. Two new alkaloids from Portulaca oleracea and their cytotoxic activities. J. Asian Nat. Prod. Res., 2014, 16(3), 259-264.
[http://dx.doi.org/10.1080/10286020.2013.866948] [PMID: 24321009]
[3]
Li, C.Y.; Meng, Y.H.; Ying, Z.M.; Xu, N.; Hao, D.; Gao, M.Z.; Zhang, W.J.; Xu, L.; Gao, Y.C.; Ying, X.X. Three novel alkaloids from Portulaca oleracea L. and their antiinflammatory effects. J. Agric. Food Chem., 2016, 64(29), 5837-5844.
[http://dx.doi.org/10.1021/acs.jafc.6b02673] [PMID: 27396870]
[4]
Zhao, R.; Gao, X.; Cai, Y.; Shao, X.; Jia, G.; Huang, Y.; Qin, X.; Wang, J.; Zheng, X. Antitumor activity of Portulaca oleracea L. polysaccharides against cervical carcinoma in vitro and in vivo. Carbohydr. Polym., 2013, 96(2), 376-383.
[http://dx.doi.org/10.1016/j.carbpol.2013.04.023] [PMID: 23768576]
[5]
Chan, K.; Islam, M.W.; Kamil, M.; Radhakrishnan, R.; Zakaria, M.N.M.; Habibullah, M.; Attas, A. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak. J. Ethnopharmacol., 2000, 73(3), 445-451.
[http://dx.doi.org/10.1016/S0378-8741(00)00318-4] [PMID: 11090998]
[6]
Mohammad, T.B.; Mohammad, H.B.; Farhad, M. Antitussive effect of Portulaca oleracea L. in guinea pigs. Iran. J. Pharm. Res., 2004, 3(3), 187-190.
[7]
Uddin, M.K.; Juraimi, A.S.; Ali, M.E.; Ismail, M.R. Evaluation of antioxidant properties and mineral composition of Purslane (Portulaca oleracea L.) at different growth stages. Int. J. Mol. Sci., 2012, 13(8), 10257-10267.
[http://dx.doi.org/10.3390/ijms130810257] [PMID: 22949859]
[8]
Chan, B.C.L.; Han, X.Q.; Lui, S.L.; Wong, C.W.; Wang, T.B.Y.; Cheung, D.W.S.; Cheng, S.W.; Ip, M.; Han, S.Q.B.; Yang, X.S.; Jolivalt, C.; Lau, C.B.S.; Leung, P.C.; Fung, K.P. Combating against methicillin-resistant Staphylococcus aureus - two fatty acids from Purslane (Portulaca oleracea L.) exhibit synergistic effects with erythromycin. J. Pharm. Pharmacol., 2015, 67(1), 107-116.
[http://dx.doi.org/10.1111/jphp.12315] [PMID: 25212982]
[9]
Meng, Y.; Ying, Z.; Xiang, Z.; Hao, D.; Zhang, W.; Zheng, Y.; Gao, Y.; Ying, X. The anti-inflammation and pharmacokinetics of a novel alkaloid from Portulaca oleracea L. J. Pharm. Pharmacol., 2016, 68(3), 397-405.
[http://dx.doi.org/10.1111/jphp.12526] [PMID: 26888212]
[10]
Eidi, A.; Mortazavi, P.; Moghadam, J.Z.; Mardani, P.M. Hepatoprotective effects of Portulaca oleracea extract against CCl4-induced damage in rats. Pharm. Biol., 2015, 53(7), 1042-1051.
[http://dx.doi.org/10.3109/13880209.2014.957783] [PMID: 25472695]
[11]
Oh, K.B.; Chang, I.M.; Hwang, K.J.; Mar, W. Detection of antifungal activity in Portulaca oleracea by a single-cell bioassay system. Phytother. Res., 2000, 14(5), 329-332.
[http://dx.doi.org/10.1002/1099-1573(200008)14:5<329:AID-PTR581>3.0.CO;2-5] [PMID: 10925396]
[12]
Radhakrishnan, R.; Zakaria, M.N.; Islam, M.W.; Chen, H.B.; Kamil, M.; Chan, K.; Al-Attas, A. Neuropharmacological actions of Portulaca oleraceae L v. sativa (Hawk). J. Ethnopharmacol., 2001, 76(2), 171-176.
[http://dx.doi.org/10.1016/S0378-8741(01)00230-6] [PMID: 11390132]
[13]
Abdel Moneim, A.E. The neuroprotective effects of purslane (Portulaca oleracea) on rotenone-induced biochemical changes and apoptosis in brain of rat. CNS Neurol. Disord. Drug Targets, 2013, 12(6), 830-841.
[http://dx.doi.org/10.2174/18715273113129990081] [PMID: 23844694]
[14]
Erkan, N. Antioxidant activity and phenolic compounds of fractions from Portulaca oleracea L. Food Chem., 2012, 133(3), 775-781.
[http://dx.doi.org/10.1016/j.foodchem.2012.01.091]
[15]
Xiu, F.; Li, X.T.; Zhang, W.J.; He, F.; Ying, X.X.; Stien, D. A new alkaloid from Portulaca oleracea L. and its antiacetylcholinesterase activity. Nat. Prod. Res., 2018.
[http://dx.doi.org/10.1080/14786419.2018.1460833] [PMID: 29665731]
[16]
Yang, X.; Zhang, W.; Ying, X.; Stien, D. New flavonoids from Portulaca oleracea L. and their activities. Fitoterapia, 2018, 127, 257-262.
[http://dx.doi.org/10.1016/j.fitote.2018.02.032] [PMID: 29501925]
[17]
Xin, H.L.; Xu, Y.F.; Hou, Y.H.; Zhang, Y.N.; Yue, X.Q.; Lu, J.C.; Ling, C.Q. Two novel triterpenoids from Portulaca oleracea L. Helv. Chim. Acta, 2010, 91(11), 2075-2080.
[http://dx.doi.org/10.1002/hlca.200890221]
[18]
Dong, C.X.; Hayashi, K.; Lee, J.B.; Hayashi, T. Characterization of structures and antiviral effects of polysaccharides from Portulaca oleracea L. Chem. Pharm. Bull. (Tokyo), 2010, 58(4), 507-510.
[http://dx.doi.org/10.1248/cpb.58.507] [PMID: 20410633]
[19]
Xu, L.; Ying, Z.; Wei, W.; Hao, D.; Wang, H.; Zhang, W.; Li, C.; Jiang, M.; Ying, X.; Liu, J. A novel alkaloid from Portulaca oleracea L. Nat. Prod. Res., 2017, 31(8), 902-908.
[http://dx.doi.org/10.1080/14786419.2016.1253081] [PMID: 27806650]
[20]
Chen, L.; Liu, Y.; Jia, D.; Yang, J.; Zhao, J.; Chen, C.; Liu, H.; Liang, X. Pharmacokinetic and biodistribution of aurantiamide and aurantiamide acetate in rats after oral administration of Portulaca oleracea L. extracts. J. Agric. Food Chem., 2016, 64(17), 3445-3455.
[http://dx.doi.org/10.1021/acs.jafc.6b00470] [PMID: 27075043]
[21]
Xu, H.R.; Zhang, W.J.; Leng, A.J.; Ying, X.X. Two new natural products from Portulaca oleracea L. and their antioxidant and antiacetylcholinesterase activities. Lat. Am. J. Pharm., 2018, 37(3), 480-483.
[22]
Food and Drug Administration. USFDA. Center for Drug Evaluation and Research (CDER). Guidance for Industry, Bi-oanalytical Method Validation. US Department of Health and Human Services. 2001. Available at. https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ (Access on: July 02, 2018).

Rights & Permissions Print Cite
Article Metrics
14
1
© 2024 Bentham Science Publishers | Privacy Policy